Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.56 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.56 |
| ▸ | CCR1 | P32246 | 2/20 | 0.53 |
| ▸ | CCR5 | P51681 | 2/20 | 0.53 |
| ▸ | CCR8 | P51685 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26964187 | 0.81 | KDM4E (0.58) | PDE10AKDM4EHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL30553418 | 0.81 | KDM4E (0.58) | PDE10AKDM4EHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL29253980 | 0.80 | PDE10A (0.60) | PDE10AKDM4EHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL27535082 | 0.80 | PDE10A (0.60) | PDE10AKDM4EHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL6431603 | 0.80 | PDE10A (0.60) | PDE10AKDM4EHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL3713823 | 0.80 | PDE10A (0.60) | PDE10AKDM4EHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL2195087 | 0.80 | PDE10A (0.60) | PDE10AKDM4EHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL8488388 | 0.80 | HSP90AA1 (0.65) | PDE10AKDM4EHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL29801038 | 0.80 | PDE10A (0.60) | PDE10AKDM4EHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL10319610 | 0.80 | PDE10A (0.55) | PDE10AHSP90AA1HSP90AB1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | disclosed |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2022173727-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-08-18 | — | — | WO | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20170260158-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-09-14 | — | — | US | disclosed |
| US-20010053783-A1 | Central nervous system disorders | FAIRHURST JOHN (GB) | 2001-12-20 | — | — | US | disclosed |
| EP-0854146-B1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | LILLY CO ELI (GB) | 2000-03-15 | — | — | EP | disclosed |
| CN-1243515-A | Substituted 4-(6-Fluoro-(1H)-indol-3-YL)-1,2,3,6-Tetra-Hydropyridine for treatment of CNS-disorders | LILLY CO ELI (GB) | 2000-02-02 | — | — | CN | disclosed |
| WO-1998031686-A1 | SUBSTITUTED 4-(6-FLUORO-(1H)-INDOL-3-YL)-1,2,3,6-TETRAHYDROPYRIDINE FOR THE TREATMENT OF CNS-DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-23 | — | — | WO | disclosed |
| EP-0854146-A1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-22 | — | — | EP | disclosed |
| US-5625068-A | Substituted quinoline herbicide intermediates and process | AMERICAN CYANAMID COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0747361-A1 | Substituted quinoline herbicide intermediates and process | American Cyanamid Company (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0132714-B1 | PROCESS FOR THE PREPARATION OF QUINOLINES | BASF Aktiengesellschaft (DE) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | PDE10A 3989/4885KDM4E 3526/4885PSMD14 1006/4885 |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | PDE10A 3989/4885KDM4E 3526/4885PSMD14 1006/4885 |
| US-20170260158-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR5A, HTR1A | PDE10A 682/4885KDM4E 3801/4885PSMD14 4067/4885 |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | PDE10A 3320/4885KDM4E 4149/4885PSMD14 2730/4885 |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | PDE10A 3989/4885KDM4E 3526/4885PSMD14 1006/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | PDE10A 3989/4885KDM4E 3526/4885PSMD14 1006/4885 |
| US-20010053783-A1 | Central nervous system disorders | CNR1, PMP22, CNR2 | PDE10A 2164/4885KDM4E 4138/4885PSMD14 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.